211 related articles for article (PubMed ID: 22117041)
1. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.
Kawedia JD; Liu C; Pei D; Cheng C; Fernandez CA; Howard SC; Campana D; Panetta JC; Bowman WP; Evans WE; Pui CH; Relling MV
Blood; 2012 Feb; 119(7):1658-64. PubMed ID: 22117041
[TBL] [Abstract][Full Text] [Related]
2. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.
Yang L; Panetta JC; Cai X; Yang W; Pei D; Cheng C; Kornegay N; Pui CH; Relling MV
J Clin Oncol; 2008 Apr; 26(12):1932-9. PubMed ID: 18421047
[TBL] [Abstract][Full Text] [Related]
3. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.
Woo MH; Hak LJ; Storm MC; Evans WE; Sandlund JT; Rivera GK; Wang B; Pui CH; Relling MV
Leukemia; 1998 Oct; 12(10):1527-33. PubMed ID: 9766495
[TBL] [Abstract][Full Text] [Related]
4. The right dose for the right patient.
Asselin BL
Blood; 2012 Feb; 119(7):1617-8. PubMed ID: 22343660
[No Abstract] [Full Text] [Related]
5. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
[TBL] [Abstract][Full Text] [Related]
6. Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Ebeid EN; Kamel MM; Ali BA
J Egypt Natl Canc Inst; 2008 Jun; 20(2):127-33. PubMed ID: 20029468
[TBL] [Abstract][Full Text] [Related]
7. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Willer A; Gerss J; König T; Franke D; Kühnel HJ; Henze G; von Stackelberg A; Möricke A; Schrappe M; Boos J; Lanvers-Kaminsky C
Blood; 2011 Nov; 118(22):5774-82. PubMed ID: 21940824
[TBL] [Abstract][Full Text] [Related]
8. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study.
Klug Albertsen B; Schmiegelow K; Schrøder H; Carlsen NT; Rosthøj S; Avramis VI; Jakobsen P
Cancer Chemother Pharmacol; 2002 Aug; 50(2):117-20. PubMed ID: 12172975
[TBL] [Abstract][Full Text] [Related]
9. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
Nowak-Göttl U; Ahlke E; Fleischhack G; Schwabe D; Schobess R; Schumann C; Junker R
Blood; 2003 Apr; 101(7):2529-33. PubMed ID: 12517808
[TBL] [Abstract][Full Text] [Related]
10. Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia-a report from the UKALL 2011 trial.
Jackson RK; Liebich M; Berry P; Errington J; Liu J; Parker C; Moppett J; Samarasinghe S; Hough R; Rowntree C; Goulden NJ; Vora A; Kearns PR; Saha V; Hempel G; Irving JAE; Veal GJ
Eur J Cancer; 2019 Oct; 120():75-85. PubMed ID: 31499383
[TBL] [Abstract][Full Text] [Related]
11. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
Tram Henriksen L; Gottschalk Højfeldt S; Schmiegelow K; Frandsen TL; Skov Wehner P; Schrøder H; Klug Albertsen B;
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660740
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
Hijiya N; Stewart CF; Zhou Y; Campana D; Coustan-Smith E; Rivera GK; Relling MV; Pui CH; Gajjar A
Cancer; 2008 May; 112(9):1983-91. PubMed ID: 18318429
[TBL] [Abstract][Full Text] [Related]
13. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
14. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
[TBL] [Abstract][Full Text] [Related]
15. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.
Mattano LA; Devidas M; Nachman JB; Sather HN; Hunger SP; Steinherz PG; Gaynon PS; Seibel NL;
Lancet Oncol; 2012 Sep; 13(9):906-15. PubMed ID: 22901620
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.
Liu C; Kawedia JD; Cheng C; Pei D; Fernandez CA; Cai X; Crews KR; Kaste SC; Panetta JC; Bowman WP; Jeha S; Sandlund JT; Evans WE; Pui CH; Relling MV
Leukemia; 2012 Nov; 26(11):2303-9. PubMed ID: 22484422
[TBL] [Abstract][Full Text] [Related]
17. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
[TBL] [Abstract][Full Text] [Related]
18. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia.
Appel IM; Hop WC; van Kessel-Bakvis C; Stigter R; Pieters R
Thromb Haemost; 2008 Aug; 100(2):330-7. PubMed ID: 18690355
[TBL] [Abstract][Full Text] [Related]
19. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
[TBL] [Abstract][Full Text] [Related]
20. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Vrooman LM; Stevenson KE; Supko JG; O'Brien J; Dahlberg SE; Asselin BL; Athale UH; Clavell LA; Kelly KM; Kutok JL; Laverdière C; Lipshultz SE; Michon B; Schorin M; Relling MV; Cohen HJ; Neuberg DS; Sallan SE; Silverman LB
J Clin Oncol; 2013 Mar; 31(9):1202-10. PubMed ID: 23358966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
